Abstrait
Les staphylocoques sont les principaux germes bactériens composant la flore cutanée normale. En revanche, le portage de streptocoques et notamment de Streptococcus pyogenes est transitoire et s’observe le plus souvent en peau lésée. Les infections cutanées secondaires à ces deux bactéries cocci à Gram positif surviennent soit directement en raison de leur caractère pathogène au sein du tissu cutané, soit indirectement par la libération de toxines agissant comme des superantigènes potentiellement responsables de chocs toxiques. Les tableaux cliniques ne permettent pas toujours de distinguer les infections streptococciques des infections staphylococciques et leur gravité varie selon la profondeur de l’atteinte cutanée et des structures impliquées (follicule pileux, épiderme, hypoderme...) (tableau 23.1).
Preview
Unable to display preview. Download preview PDF.
Références
Neu HC. The crisis in antibacterial resistance. Science 1992; 257:1064–1073.
Espersen F. Resistance to antibiotics used in dermatological practice. Br J Dermatol 1998; 139(Suppl 53):9–12.
Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520–532.
Wertheim HF, Melles DC, Vos MC et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005; 5:751–562.
Kuroda M, Ohta T, Uchiyama I et al. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 200; 357:1225–1240.
Skinner D, Keefer CS. Significance of bacteraemia caused by staphylococcus. Arch Intern Med 1941; 68:851–875.
Katayama Y, Zhang H, Hong D, Chambers H. Jumping the barrier to b-lactam resistance in Staphylococcus aureus. J Bacteriol 2003; 185:5465–5472.
Jevons MP, Coe AW, Parker MT. Celbeninresistants staphylococci. Methicillin resistance in staphylococci. Lancet 1963; 1:904–907.
Zetola N, Francis J, Nuermberger E, Bishai W. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Inf Dis 2005; 5:275–286.
Boyce JM, Cookson B, Christiansen K et al. Meticillin-resistant Staphylococcus aureus. Lancet Inf Dis 2005; 5:653–663.
Robinson DA, Kearns AM, Holmes A et al. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillinresistant clone. Lancet 2005; 365:1256–1258.
Wielders C, Vriens M, Brisse S et al. In-vivo transfer of mecA DNA to Staphylococcus aureus. Lancet 2001; 357:1674–1675.
Oliveira D, Tomasz A, de Lencastre H. Secrets of success of a human pathogen: molecular evolution of pandemic clones of meticillinresistant Staphylococcus aureus. Lancet Infect Dis 2002; 2:180–189.
Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 2003; 51:1109–1117.
Naimi T, LeDell K, Como-Sabetti K et al. Comparison of Community-and Health Care-Associated Methicillin-Resistant Staphylococcus aureus Infection. JAMA 2003; 290:2976–2984.
John CC. Vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 341:207–208.
Bernard P. Du bon usage des antibiotiques locaux en dermatologie. Ann Dermatol Venereol 2004; 131:941–943.
Speller D, Johnson A, James D et al. Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989–1995. Lancet 1997; 350:323–325.
Lancefield RC. A serological differentiation of human and other groups of haemolytic streptococci. J Exp Med 1933; 57:571–595.
Vinh D, Embil J. Rapidly progressive soft tissue infections. Lancet Infect Dis 2005; 5:501–513.
Carapetis J, Steer A, Mulholland E, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685–694.
Bisno A, Stevens D. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334:240–245.
Halpern MT, Schmier JK, Snyder LM et al. Meta-analysis of bacterial resistance to macrolides. J Antimicrob Chemother 2005; 55:748–757.
Grivea IN, Al-Lahham A, Katopodis GD et al. Resistance to Erythromycin and Telithromycin in Streptococcus pyogenes Isolates Obtained between 1999 and 2002 from Greek Children with Tonsillopharyngitis: Phenotypic and Genotypic Analysis. Antimicrob Agents Chemother 2006; 50:256–261.
Seppala H, Skurnik M, Soini H et al. The effect of change in consumption of macrolide on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337:441–446.
Makhoul IR, Kassis I, Hashman N, Sujov P. Staphylococcal scalded-skin syndrome in a very low birth weight premature infant. Pediatrics 2001; 108:E16.
Koning S, van der Wouden JC. Treatment for impetigo. BMJ 2004; 329:695–696.
Koning S, Verhagen AP, van Suijlekom-Smit LW et al. Interventions for impetigo. Cochrane Database Syst Rev 2004:CD003261.
Recommandations AFSSAPS: prescription des antibiotiques par voie locale dans les infections cutanées bactériennes primitives et secondaires. Ann Dermatol Venereol 2004; 131:1018–1021.
Luby SP, Agboatwalla M, Feikin DR et al. Effect of handwashing on child health: a randomised controlled trial. Lancet 2005; 366:225–233.
Chosidow O, Bernard P, Berbis P et al. Cloxacillin versus Pristinamycin for superficial pyodermas: a randomised, open-label, noninferiority study. Dermatology 2005; 210:370–374.
Perry P, Cook-Bolden F, Rahman Z et al. Defining pseudofolliculitis barbae in 2001: a review of the literature and current trends. J Am Acad Dermatol 2002; 46(Suppl 2):S113–119.
Issartel B, Tristan A, Lechevallier S et al. Frequent carriage of Panton-Valentine leucocidin genes by Staphylococcus aureus isolates from surgically drained abscesses. J ClinMicrobiol 2005; 43:3203–3207.
Hoss DM, Feder HM jr. Addition of rifampicin to conventional therapy for recurrent furunculosis. Arch Dermatol 1995; 131:647–648.
Papageorgiou AC, Acharya KR. Microbial superantigens: from structure to function. TrendsMicrobiol 2000; 8:369–375.
Machado C, Schubach A, Conceiçao-Silva F et al. Botriomycosis. Dermatology 2005; 211:303–304.
Schneider JA, Parlette HR 3rd. Blistering distal dactylitis: a manifestation of group A beta-hemolytic streptococcal infection. Arch Dermatol 1982; 118:879–880.
Llewlyn M, Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002; 2:156–162.
Acharya KR, Passalacqua EF, Jones EY et al. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. Nature 1994; 367:94–97.
Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248:705–711.
Kotb M, Norrby-Teglund A, McGeer A et al. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002; 8:1398–1404.
Cribier B, Piemont Y, Grosshans E. Staphylococcal scalded skin syndrome in adults. J Am Acad Dermatol 1994; 30:319–324.
Hanakawa Y, Schechter NM, Lin C et al. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. J Clin Invest 2002; 110:53–60.
Amagai M, Matsuyoshi N, Wang ZH et al. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med 2000; 6:1275–1277.
Rago JV, Vath GM, Bohach GA et al. Mutational analysis of the superantigen staphylococcal exfoliative toxin A (ETA). J Immunol 2000; 164:2207–2213.
Norrby-Teglund A, Thulin P, Gan BS et al. Evidence for superantigen involvement in severe group a streptococcal tissue infections. J Infect Dis 2001; 184:853–860.
Mc Cormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu RevMicrobiol 2001; 55:77–104.
Kikuchi K, Takahashi N, Piao C et al. Molecular epidemiologyof methicillin-resistant staphylococcus aureus strains causing neonatal toxic shock syndrome-like exanthematous disease inneonatal and perinatal wards. J ClinMicrobiol 2003: 41:3001–3006.
Kaul R, McGeer A, Norrby-Teglund A et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999; 28:800–807.
Braun MA, Gerlach D, Hartwig UF et al. Stimulation of human T cells by streptococcal « superantigen » erythrogenic toxins (scarlet fever toxins). J Immunol 1993; 150:2457–2466.
Manders SM. Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol 1998; 39:383–398.
Conférence de consensus: érysipèle et fasciite nécrosante: prise en charge. Ann Dermatol Venereol 2001; 128:307–482.
Dupuy A, Benchikhi H, Roujeau JC et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. Br Med J 1999; 318:1591–1594.
Estines O, Coste N, Perceau G et al. Érysipèle hémorragique: intérêt d’une courte corticothérapie adjuvante. Ann Dermatol Venereol 2003; 130:523–526.
Coste N, Perceau G, Leone J et al. Osteoarticular complications of erysipelas. J Am Acad Dermatol 2004; 50:203–209.
Bernard P, Bedane C, Mounier M et al. Dermohypodermites bactériennes de l’adulte. Incidence et place de l’étiologie streptococcique. Ann Dermatol Venereol 1995; 122:495–500.
Bernard P, Chosidow O, Vaillant L. Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adult patients: randomised, non-inferiority, open trial. Br Med J 2002; 325:864–866.
Bernard P, Plantin P, Roger H et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol 1992; 127:155–159.
Hasham S, Matteuci P, Stanley PR, Hart NB. Necrotising fasciitis. Br Med J 2005; 330:830–863.
Pao W, Duncan KO, Bolognia JL et al. Numerous eruptive lesions of panniculitis associated with group A streptococcus bacteremia in an immunocompetent child. Clin Infect Dis 1998; 27:430–433.
Fluit AC, Wielders CL, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J ClinMicrobiol 2001; 39:3727–3732.
Chiller K, Selkin BA, Murakawa GJ. Skin microflora and bacterial infections of the skin. J Investig Dermatol Symp Proc 2001; 6:170–174.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag France, Paris
About this chapter
Cite this chapter
Reguiaï, Z., Bernard, P. (2008). Infections cutanées staphylococciques et streptococciques. In: Manifestations dermatologiques des maladies infectieuses, métaboliques et toxiques. Springer, Paris. https://doi.org/10.1007/978-2-287-48494-0_2
Download citation
DOI: https://doi.org/10.1007/978-2-287-48494-0_2
Publisher Name: Springer, Paris
Print ISBN: 978-2-287-48493-3
Online ISBN: 978-2-287-48494-0